Evidence map›Paper›PMID 35984492›Full record

ArticleJournal of cancer research and clinical oncology2023

Neferine, a novel ROCK1-targeting inhibitor, blocks EMT process and induces apoptosis in non-small cell lung cancer.

Po Hu, Peng Wan, Anna Xu, Binghui Yan, Chunmei Liu, Qixuan Xu, Zhenhuan Wei, Jingyi Xu, Siqi Liu, Guangming Yang and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Po Hu *School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.ORCID http://orcid.org/0000-0002-1347-4809
Peng Wan *School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Anna XuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Binghui YanSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Chunmei LiuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Qixuan XuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Zhenhuan WeiSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Jingyi XuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Siqi LiuSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China.
Guangming YangSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China. ygm@njucm.edu.cn.
Yang PanSchool of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210023, China. ypan@njucm.edu.cn.
Nanjing University of Chinese Medicine · CN

Funding

Innovative Research Group Project of the National Natural Science Foundation of China 81373295Innovative Research Group Project of the National Natural Science Foundation of China 81473420Innovative Research Group Project of the National Natural Science Foundation of China BK20220474the Open Project of State Key Laboratory of Natural Medicines SKLNMKF202202
6 · The paper itself

Abstract

The compounds derived from Traditional Chinese Medicines have shown various pharmacological activities with unique advantages, especially in the aspect of antitumor. Neferine (Nef), a natural compound, extracted from green seed embryos of Lotus (Nelumbo nucifera Gaertn.) also exerts antitumor effects on cancers. In this study, the effects and mechanisms of Nef on epithelial-to-mesenchymal transition (EMT) process in non-small cell lung cancer (NSCLC) were evaluated. The results showed that Nef had the antitumor effects in vivo and in vitro. Nef significantly suppressed cell viability and induced apoptosis in NSCLC cells, with elevated reactive oxygen species and reduced BCL2/BAX ratio. Nef was also demonstrated to inhibit the invasion, metastasis and EMT process of NSCLC cells, and attenuate EMT-related changes of E-cadherin, N-cadherin and Vimentin at both transcriptional and translational levels. Moreover, we concluded that the inhibitory effects of Nef on EMT was achieved by targeting Rho-associated protein kinase 1, a protein mediating the process of EMT in various cancers. These results showed that Nef had a significant antitumor effect on NSCLC cells by inducing apoptosis and blocking EMT, providing the therapeutical prospect on NSCLC treatment.

Indexed as

Carcinoma, Non-Small-Cell LungLung Neoplasmsrho-Associated KinasesApoptosisBenzylisoquinolinesCell Line, TumorCell MovementEpithelial-Mesenchymal TransitionHumansBenzylisoquinolinesneferinerho-Associated KinasesROCK1 protein, humanApoptosisEpithelial-to-mesenchymal transitionNatural compoundNeferineNon-small cell lung cancerRho-associated protein kinase 1

Identifiers

PMID35984492
PMCPMC11797308
OpenAlexW4292316389

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.